Idaho has reached a $13 million settlement with drug manufacturer Eli Lilly & Co., the state's biggest financial recovery under the Idaho Consumer Protection Act aside from the 1998 tobacco settlement. The state sued the pharmaceutical manufacturer over its marketing of Zyprexa, an anti-psychotic drug, saying the drug company "engaged in deceptive marketing" and "failed to warn health care providers of serious side effects, resulting in significant costs to Idaho Medicaid." Part of the money will go to reimburse the federal government, which pays part of the cost of Idaho's Medicaid program, while about $6.9 million will go to the state's general fund. "Off-label promotion of pharmaceutical drugs is a deceptive practice and creates unnecessary risks to consumers," Idaho Attorney General Lawrence Wasden said. "In this instance, the company's practices also resulted in additional costs to Idaho Medicaid, at the expense of Idaho taxpayers.